These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9316822)

  • 41. Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.
    Luszczki JJ; Ratnaraj N; Patsalos PN; Czuczwar SJ
    Epilepsia; 2006 Nov; 47(11):1841-54. PubMed ID: 17116023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children.
    Rauchenzauner M; Haberlandt E; Scholl-Bürgi S; Karall D; Schoenherr E; Tatarczyk T; Engl J; Laimer M; Luef G; Ebenbichler CF
    Epilepsy Res; 2008 Aug; 80(2-3):142-9. PubMed ID: 18472247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Valproic acid glucuronidation is associated with increases in 15-F2t-isoprostane in rats.
    Tong V; Teng XW; Karagiozov S; Chang TK; Abbott FS
    Free Radic Biol Med; 2005 Jun; 38(11):1471-83. PubMed ID: 15890621
    [TBL] [Abstract][Full Text] [Related]  

  • 44. S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.
    Eikel D; Hoffmann K; Zoll K; Lampen A; Nau H
    Drug Metab Dispos; 2006 Apr; 34(4):612-20. PubMed ID: 16415118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children.
    Ueshima S; Aiba T; Makita T; Nishihara S; Kitamura Y; Kurosaki Y; Kawasaki H; Sendo T; Ohtsuka Y; Gomita Y
    J Clin Pharm Ther; 2008 Feb; 33(1):31-8. PubMed ID: 18211614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum and liver tissue biotinidase enzyme activity in rats which were administrated to valproic acid.
    Korkmazer N; Vurucu S; Demirkaya E; Unay B; Kul M; Akin R; Gokcay E
    Brain Dev; 2006 Sep; 28(8):515-20. PubMed ID: 16682156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of sodium valproate and its metabolites (5-OH-VPA and 4-OH-VPA) on electroconvulsions in rats.
    Sobaniec W; Sobaniec-Lotowska M
    Mater Med Pol; 1994; 26(1):29-32. PubMed ID: 7808038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disposition of beta-glucuronidase-resistant "glucuronides" of valproic acid after intrabiliary administration in the rat: intact absorption, fecal excretion and intestinal hydrolysis.
    Dickinson RG; Kluck RM; Eadie MJ; Hooper WD
    J Pharmacol Exp Ther; 1985 Apr; 233(1):214-21. PubMed ID: 3920383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Contribution of probenecid-sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system.
    Adkison KD; Artru AA; Powers KM; Shen DD
    J Pharmacol Exp Ther; 1994 Feb; 268(2):797-805. PubMed ID: 8113992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Reed RC; Dutta S
    Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.
    Fattore C; Messina S; Battino D; Croci D; Mamoli D; Perucca E
    Epilepsy Res; 2006 Aug; 70(2-3):153-60. PubMed ID: 16730950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impaired biliary elimination of beta-glucuronidase-resistant "glucuronides" of valproic acid after intravenous administration in the rat. Evidence for oxidative metabolism of the resistant isomers.
    Dickinson RG; Kluck RM; Wood BT; Eadie MJ; Hooper WD
    Drug Metab Dispos; 1986; 14(2):255-62. PubMed ID: 2870903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of valproic acid on glycine conjugation of benzoic acid.
    Gregus Z; Fekete T; Varga F; Klaassen CD
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1068-75. PubMed ID: 8263766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.
    Shimshoni JA; Bialer M; Wlodarczyk B; Finnell RH; Yagen B
    J Med Chem; 2007 Dec; 50(25):6419-27. PubMed ID: 17994680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model.
    Serralta A; Barcia JA; Ortiz P; Durán C; Hernández ME; Alós M
    Epilepsy Res; 2006 Jul; 70(1):15-26. PubMed ID: 16616829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beneficial interaction between vigabatrin and valproate against seizures induced by pentylenetetrazole in mice.
    Cuadrado A; Armijo JA
    Pharmacol Res; 2005 May; 51(5):489-96. PubMed ID: 15749465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Teratogenicity of valproate conjugates with anticonvulsant activity in mice.
    Spiegelstein O; Chatterjie N; Alexander G; Finnell RH
    Epilepsy Res; 2003 Dec; 57(2-3):145-52. PubMed ID: 15013055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stereoselective dysmorphogenicity of the enantiomers of the valproic acid analogue 2-N-propyl-4-pentynoic acid (4-yn-VPA): cross-species evaluation in whole embryo culture.
    Andrews JE; Ebron-McCoy MT; Bojic U; Nau H; Kavlock RJ
    Teratology; 1997 May; 55(5):314-8. PubMed ID: 9261925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.
    Luszczki JJ; Czuczwar P; Cioczek-Czuczwar A; Czuczwar SJ
    Eur J Pharmacol; 2006 Oct; 547(1-3):65-74. PubMed ID: 16930590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.